Skip to main content
Login
Contact
Subscribe
Search form
Search
Starkville Daily News
Home
Forms
News
Sports
Classifieds
Place a Classified Ad
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Astrazeneca Plc
(NY:
AZN
)
47.98
USD
+0.21 (+0.44%)
Official Closing Price
/ Updated:
6:30 PM EST, Dec 10, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
3,441,300
Open
47.47
Bid (Size)
47.48 (1)
Ask (Size)
50.77 (6)
Prev. Close
47.77
Today's Range
47.45 - 48.04
52wk Range
35.30 - 49.22
Shares Outstanding
2,533,294,824
Dividend Yield
2.86%
Performance
YTD
+26.93%
+26.93%
1 Month
+2.35%
+2.35%
3 Month
+10.89%
+10.89%
6 Month
+21.81%
+21.81%
1 Year
+24.92%
+24.92%
Top News
More News
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
December 07, 2019
AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly...
Read More
from
Business Wire News Releases
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
December 07, 2019
Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.
Read More
category
Pharma/Biotech
,
Stocks / Equities
from
Blogs - TalkMarkets
More News
Read More
Week in Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
December 07, 2019
from
ChinaBio® Today
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
December 05, 2019
from
ChinaBio® Today
REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
December 05, 2019
category
companyNews
from
Reuters: Company News
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
December 05, 2019
from
ChinaBio® Today
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
December 05, 2019
category
companyNews
from
Reuters: Company News
China to use drug bulk-buy program to close price gap
November 30, 2019
category
companyNews
from
Reuters: Company News
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
November 29, 2019
category
Futures
,
Benzinga
,
TECD
, and 11 more.
from
Benzinga
Is Clovis Oncology Really a Buyout Candidate?
December 03, 2019
category
CLVS
,
AZN
,
JNJ
, and 3 more.
from
Motley Fool
China Adds 70 Drugs to Insurance Reimbursement List; Negotiates 61% Average Price Cuts
December 02, 2019
from
ChinaBio® Today
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.